Xeris Biopharma Holdings Inc (XERS)
EBITDA Growth
-343.70%
Quarterly · Period ending:
XERS EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-343.70%period ending
Latest reported-343.70%period ending
XERS Quarterly EBITDA YoY % (-152.72% → -343.70%)
Year-over-year change
High-resolution chart · PNG
XERS ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| -343.7049% | |
| 903.9088% | |
| 146.8461% | |
| 235.893% | |
| 373.8687% | |
| 114.5722% | |
| 270.8868% | |
| -250.9255% | |
| 70.4687% | |
| -13.3118% | |
| 37.9585% | |
| 84.6261% | |
| 46.9072% | |
| 73.024% | |
| 88.7764% | |
| 36.7465% | |
| 21.2047% | |
| -69.3116% | |
| -185.9394% | |
| -79.7577% | |
| -17.3264% | |
| 40.497% | |
| 46.821% | |
| 54.1601% | |
| 34.5912% | |
| -13.642% | |
| -64.8202% | |
| -106.7023% | |
| -168.0651% | |
| -106.6421% | |
| -111.0879% | |
| -86.5027% | |
| -139.005% | |
| -152.7218% |